{
  "guideline": {
    "id": "PA166265141",
    "name": "Annotation of DPWG Guideline for allopurinol and HLA-B",
    "source": "DPWG",
    "version": 3,
    "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166265141",
    "relatedChemicals": [
      {
        "id": "PA448320",
        "name": "allopurinol",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA35056",
        "name": "major histocompatibility complex, class I, B",
        "symbol": "HLA-B"
      }
    ],
    "recommendation": true,
    "guidelineGenes": [
      {
        "alleles": [
          {
            "id": 1451697700,
            "_label": "*58:01",
            "function": {
              "term": "Presence",
              "termId": "haplotypeTags:1445558333"
            }
          },
          {
            "id": 1451698856,
            "_label": "Other",
            "function": {
              "term": "Absence",
              "termId": "haplotypeTags:1445558334"
            }
          }
        ],
        "gene": {
          "chr": {
            "id": "PA532",
            "name": "chr6",
            "symbol": null
          },
          "strand": "minus",
          "id": "PA35056",
          "name": "major histocompatibility complex, class I, B",
          "symbol": "HLA-B"
        }
      }
    ]
  },
  "annotationGroups": [
    {
      "id": "PA166265407",
      "name": "*58:01 negative",
      "strength": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "rxChangeStatus": {
        "term": "No",
        "termId": "rxChange:1448602495"
      },
      "genePhenotypes": [
        "HLA-B:Absence/Absence"
      ],
      "metabolizerStatus": null,
      "recommendation": {
        "id": 1451782579,
        "html": "<p>The guideline does not provide a recommendation for allopurinol in patients with no HLA-B*58:01 alleles or negative for the HLA-B*58:01 test.</p>\n"
      },
      "implications": {
        "id": 1451782578,
        "html": "<p>The guideline does not provide a description of the impact of the absence of HLA-B*58:01 alleles on allopurinol.</p>\n"
      },
      "activityScore": null
    },
    {
      "id": "PA166265406",
      "name": "*58:01 positive",
      "strength": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "rxChangeStatus": {
        "term": "Yes",
        "termId": "rxChange:1448602497"
      },
      "genePhenotypes": [
        "HLA-B:Absence/Presence",
        "HLA-B:Presence/Presence"
      ],
      "metabolizerStatus": null,
      "recommendation": {
        "id": 1451782577,
        "html": "<ul>\n<li>\n<p>Choose an alternative, such as febuxostat</p>\n</li>\n<li>\n<p>Another option is to induce allopurinol tolerance first: To induce allopurinol tolerance, the allopurinol dose is increased every 3 days until a dose of 100 mg/day has been achieved on Day 28. The consecutive daily doses in the\ninduction protocol are 50 µg, 100 µg, 200 µg, 500 µg, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg and 100 mg.</p>\n</li>\n</ul>\n"
      },
      "implications": {
        "id": 1451782576,
        "html": "<p>A strongly increased risk of developing the life-threatening cutaneous side effects Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) and DRESS is present in\npatients with this genetic variation. The risk of an allopurinol-induced life-threatening cutaneous side effect (mortality 11%) in these patients is 1.6-2.0% for the entire group\nand 8-18% for the group with chronic renal insufficiency.</p>\n"
      },
      "activityScore": null
    }
  ],
  "citations": []
}